Pharmaceutical Care on A Patient with Low Molecular Weight Heparin Calium-induced Thrombocytopenia / 医药导报

Objective To provide reference for clinical pharmacists participating in pharmacotherapy of low molecular weight heparin calium-induced thrombocytopenia.Methods Clinical pharmacists carried out pharmaceutical care for a patient with chronic cor pulmonale with acute exacerbation of chronic asthmatic bronchitis in the use of low molecular weight heparin calium,who developed progressive thrombocytopenia,and helped clinicians to manage adverse reaction and select subsequent treatment drug.Results The suggestions were adopted by clinicians.The platelets of patients gradually recovercd without thrombosis events.Condusion Participation of clinical pharmacists in the treatment of low molecular weight heparin calium induced-thrombocytopenia can effectively improve the prognosis of patients and ensure the safety in drug use.

Effects of low molecular weight heparin calcium combined with breviscapini on plasma NO and ET-1 in acute exacerbation of elderly chronic pulmonary heart disease / 国际检验医学杂志

Objective To investigate the effect of low molecular weight heparin calcium combined with breviscapini in treating a-cute exacerbation of elderly chronic pulmonary heart disease and its mechanism.Methods 86 patients with acute exacerbation of elderly chronic pulmonary heart disease in our hospital from October 2011 to June 2013 were randomly divided into two groups. There were no significant differences in age,gender and disease condition between the two groups.44 cases were in the therapy group and the other 42 cases were in the control group.Both two groups received the routine therepy.On this basis the therapy group was added with low molecular weight heparin calcium and breviscapini.Then the improvement of clinical symptoms and the changes of plasma nitric oxide (NO)and endothelin-l (ET-1)after treatment were observed in the two groups.Results The total effective rates in the therapy group and the control group were 90.1%and 71.4% respectively;the levels of plasma NO and ET-1 after treatment in the two groups were significantly improved,but the improvement in the therapy group was better than that in the control group with the statistical difference between them(P <0.05).Conclusion Low molecular weight heparin calcium combined with breviscapini can significantly improve the symptoms in the ederly pulmonary heart disease,decrease the lung arterial press,re-lieve the load of right ventricle and affect the levels of plasma NO and ET-1 with less adverse reactions.